CCL3 to improve healing of diabetic foot ulcers
Assessment of CCL3 Therapy in Diabetic Wound Care
Testing whether a medicine called CCL3 can help people with diabetes heal foot ulcers by restoring the wound’s immune response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11260243 on NIH RePORTER |
What this research studies
This research will test applying CCL3, a natural immune-signaling protein, to diabetic wounds to bring key infection-fighting white blood cells into the wound early. Researchers will use laboratory and animal wound models and examine human wound samples to see if CCL3 restores neutrophil movement and improves bacterial clearance against germs like Pseudomonas and Staphylococcus. They will track signs of infection, bacterial amounts, inflammation, and how quickly wounds close. If results look promising, the team aims to move toward trials that enroll people with diabetic foot ulcers.
Who could benefit from this research
Good fit: Ideal candidates would be adults with diabetes who have non-healing or newly infected foot ulcers and are willing to provide wound samples or travel to the research site.
Not a fit: People without diabetic foot ulcers, or those whose wounds are primarily due to severe blood flow problems or extensive tissue loss, may not benefit from this approach.
Why it matters
Potential benefit: If successful, CCL3 treatment could lower wound infections and reduce the risk of amputations by helping diabetic foot ulcers heal faster.
How similar studies have performed: Some preclinical work supports using chemokines to recruit immune cells, but CCL3 therapy for diabetic wounds is largely preclinical and has not been widely tested in people.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Shafikhani, Sasha H — University of California at Davis
- Study coordinator: Shafikhani, Sasha H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.